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Abstract
Calcium is a key signaling ion involved in many different intracellular and extracellular processes
ranging from synaptic activity to cell-cell communication and adhesion. The exact definition at the
molecular level of the versatility of this ion has made overwhelming progress in the past several
years and has been extensively reviewed. In the brain, calcium is fundamental in the control of
synaptic activity and memory formation, a process that leads to the activation of specific calcium-
dependent signal transduction pathways and implicates key protein effectors, such as CaMKs,
MAPK/ERKs, and CREB. Properly controlled homeostasis of calcium signaling not only supports
normal brain physiology but also maintains neuronal integrity and long-term cell survival. Emerging
knowledge indicates that calcium homeostasis is not only critical for cell physiology and health, but
also, when deregulated, can lead to neurodegeneration via complex and diverse mechanisms
involved in selective neuronal impairments and death. The identification of several modulators of
calcium homeostasis, such as presenilins and CALHM1, as potential factors involved in the
pathogenesis of Alzheimer's disease, provides strong support for a role of calcium in
neurodegeneration. These observations represent an important step towards understanding the
molecular mechanisms of calcium signaling disturbances observed in different brain diseases such
as Alzheimer's, Parkinson's, and Huntington's diseases.
Calcium signaling and neuronal functions in the 
healthy brain
Brain functions are manifested at specific synapses
through release of neurotransmitters inducing a number
of biochemical signaling events in postsynaptic neurons.
One of the most prominent of these events is a rapid and
transient rise in calcium levels. This local increase in cal-
cium concentrations results in a number of short-term
and long-term synapse-specific alterations. These include
the insertion or removal of specific calcium channel sub-
units at or from the membrane and the post-translational
modification or degradation of synaptic proteins [1-3].
Beside these local events at the synapse, calcium elevation
in postsynaptic neurons activates a cascade of signaling
events that result in gene expression and that are essential
for dendritic development, neuronal survival, and synap-
tic plasticity [4,5] (Figure 1).
Under resting conditions, free cytosolic calcium levels in
neurons are maintained around 200 nM. Upon electrical
or receptor-mediated stimulation, calcium levels rise to
low micromolar concentrations by a mechanism of extra-
cellular calcium influx or calcium release from intracellu-
lar stores. Extracellular calcium concentrations are several
magnitudes higher compared to cytosolic calcium levels.
Thus, calcium can enter the cells during opening of spe-
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cific ion channels, which include the voltage-gated cal-
cium channels (VGCCs) and several ligand-gated ion
channels, such as glutamate and acetylcholine receptors
[6,7]. The main intracellular calcium store is the endo-
plasmic reticulum (ER) from where calcium can be
released into the cytosol via activation of the inositol
1,4,5-triphosphate receptors (InsP3Rs) or ryanodine
receptors (RyRs) [6]. Basal cytosolic calcium levels are in
part maintained by powerful calcium-binding and cal-
cium-buffering proteins (e.g. calbindin or parvalbumin)
or by active uptake into internal stores by the Sarco/ER
calcium-ATPase (SERCA) at the ER membrane or by the
mitochondrial uniporter [6].
Calcium signaling and synaptic activity
Synaptic plasticity is thought to be crucial for information
processing in the brain and to underlie learning and mem-
ory. Widely studied models for synaptic plasticity are
long-term potentiation (LTP) and long-term depression
(LTD). LTP is a cellular model underlying learning and
memory, which has been described in all excitatory path-
ways in the hippocampus and in different other brain
regions [8,9].
LTP is usually divided into three temporal phases. The first
stage is initial LTP or referred as short-term potentiation
(STP) and is characterized as being protein-kinase and
protein-synthesis independent. The next phase is early
LTP (E-LTP) and its expression is mediated by activation
of various protein kinases and the insertion of glutamate
receptors into the postsynaptic membrane [10,11]. The
third phase is late LTP (L-LTP) and lasts from a few hours
to several days and is correlated to long-term memory.
The critical biochemical feature for L-LTP is a requirement
for new gene expression and protein synthesis [12-14]. An
essential event necessary for the induction of all types of
LTP appears to be the influx of calcium into the postsyn-
aptic spine. Indeed, LTP induction can occur when posts-
ynaptic hippocampal neurons are loaded with calcium
[15]. Conversely, LTP can be blocked with calcium chela-
tors preventing the postsynaptic rise in calcium [15-19].
Extracellular calcium influx is not, however, the only
event controlling LTP. Depletion of ER calcium stores can
block LTP, suggesting that calcium release from intracellu-
lar stores is also critical for LTP induction (see next para-
graph and Ref. [9]).
In the majority of synapses that support LTP, the postsyn-
aptic increase in calcium is mediated by the N-methyl-D-
aspartate receptor (NMDAR) [20-22]. The requirement for
NMDAR activity in LTP was not only demonstrated in the
hippocampus, but also in other brain regions, such as the
amygdala [23] and frontal cortex [24]. In addition animal
studies confirmed the importance of NMDAR for learning
and memory, by showing that NMDAR inhibition
blocked spatial and associative learning [25-28]. LTP
induction, however, can also occur in the CA1 region as a
result of L-type VGCC activation [29,30]. Furthermore,
several studies have shown that intracellular calcium
stores may also play a role in the increase of postsynaptic
calcium levels upon synaptic activity. Indeed, depletion of
ER calcium stores with thapsigargin has been shown to
inhibit the induction of LTP in brain hippocampal slices
[31-33] and inhibition of the ER calcium channels RyRs or
InsP3Rs appeared to affect specific LTP forms [30,33,34].
Calcium signaling and CaMKs
The rise in intracellular calcium levels upon synaptic activ-
ity triggers the activation of several kinases critical for the
induction and expression of LTP. These include the cal-
cium/calmodulin-regulated protein kinases CaMKII and
CaMKIV [35], the cAMP-dependent protein kinase A
(PKA) [36], PKC [37,38] and MAPK/ERKs. A broad range
of evidence from molecular, cellular, and transgenic ani-
mal studies established CaMKII as a key factor in LTP.
Postsynaptic injection of CaMKII inhibitors or genetic
deletion of a critical CaMKII subunit blocked the ability to
generate LTP and impaired learning in mice
[10,37,39,40]. In addition, enhancing postsynaptic CaM-
KII activity in CA1 neurons was able to induce synaptic
potentiation and subsequent induction of LTP [41,42].
Some of the consequences of CaMKII activation are an
increase of the calcium conductance of the glutamate
receptor AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxa-
zole propionic acid receptor), and this by a mechanism of
phosphorylation of the channel by CaMKII and by
Calcium signaling in synaptic plasticity Figure 1
Calcium signaling in synaptic plasticity. Synaptic activity 
results in the elevation of cytosolic calcium levels by promot-
ing extracellular calcium influx (through opening of specific 
cell surface calcium channels, e.g. VGCCs or NMDAR) or ER 
calcium efflux (via activation of RyRs or InsP3Rs). Increased 
cytosolic calcium concentrations initiate the activation of sev-
eral kinase-dependent signaling cascades leading to CREB 
activation and phosphorylation at Ser133, a process critical 
for protein synthesis-dependent synaptic plasticity and LTP.
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increasing AMPAR recycling. Both of these effects repre-
sent a way to regulate the strength of glutamergic synapses
[43-45].
Calcium signaling and MAPK/ERKs
One of the protein kinase families critical for the expres-
sion of LTP is the MAP kinase family, specifically the extra-
cellular signal-regulated kinases (ERKs). ERKs belong to
the large family of mitogen-activated protein kinases
(MAPKs) which have a vital role in differentiation and
proliferation in dividing cells. ERKs are also highly
expressed in the adult brain, specifically in mature neu-
rons, which are terminally differentiated and do not
divide [46].
The MAPK/ERK cascade involves a consecutive and
sequential activation of 3 kinases. The upstream MAPK
kinase-kinases Raf phosphorylate MAPK/ERK-kinases
(MEKs). MEKs are dual specific kinases that trigger the
activation of MAPKs by phosphorylating a threonine and
tyrosine. Phosphorylation of both residues is required for
ERK activation. ERK is phosphorylated during NMDAR
activation in the hippocampal CA1 region during LTP
[47,48] and in cultured embryonic hippocampal neurons
[49], demonstrating ERK involvement in synaptic plastic-
ity [50-53].
It appears that activation of the MAPK/ERK cascade by cal-
cium can be mediated by different pathways. One of these
pathways is Ras-dependent. Ras represents one super-
family of small GTPases, which function as a molecular
switch by cycling between an inactive GDP-bound state
and an active GTP-bound state. This process is facilitated
by guanine nucleotide exchange factors (GEFs) for activa-
tion and GTPase-activating proteins (GAPs) for inhibition
of Ras. RasGRF1, a calcium/CaM-dependent GEF, inter-
acts with the NR2B subunit of NMDAR and mediates acti-
vation of the calcium channel and of the Ras/Raf/ERK
cascade in hippocampal neurons [54,55]. A novel Ras-
GAP, p135 SynGAP, which is highly abundant at
glutaminergic synapses, is reversibly inhibited by CaMKII
[56]. This inhibition could stop the inactivation of GTP-
bound Ras and thus initiate MAPK/ERK cascade activa-
tion.
In addition to Ras, PKA and PKC appear to be required for
MAPK activation in cell culture models and hippocampal
slices [57-59]. Further experiments also showed that PKA
is required for nuclear translocation of ERK. The abundant
crosstalk between these different kinase pathways suggests
that the ERK cascade may represent a point of convergence
from several kinases activated as a consequence of LTP
induction and calcium elevation in the post-synaptic ter-
minal [9,60] (Figure 1).
Even though the ERK family comprises 5 different iso-
forms, ERK1 through ERK5, ERK1 and ERK2 are the most
studied in synaptic plasticity. The two kinases show nearly
85% sequence identity and are both highly expressed
throughout the brain and in postmitotic neurons [46,61].
In some cases, however, ERK1 and ERK2 activation is dif-
ferentially regulated. ERK2, but not ERK1, is activated in
the CA1 region of the hippocampus after LTP induction
[47]. In rats, ERK2 was selectively activated after contex-
tual fear conditioning [62]. Whereas genetic ablation of
ERK1 has no severe general phenotypic consequences
[63,64], an ERK1 knockout mouse model was found to
display significant enhancement of striatum-dependent
long-term memory/LTP [65]. In contrast to ERK1, ERK2
knockout animals are embryonic lethal [51]. Conditional
ERK2 inactivation revealed that ERK2 deficiency in the
brain results in a reduction of cortical brain thickness and
in the generation of fewer neurons [66]. Together, these
data clearly suggest a different role for both ERK isoforms,
with ERK1 possibly playing an accessory function to ERK2
during LTP and neuronal calcium signaling.
Calcium signaling and CREB
It is well established that changes in intracellular calcium
levels in neurons are transduced into protein synthesis
through activation of specific signaling pathways and
transcription factors. Protein synthesis is indeed required
for persistent forms of synaptic plasticity, including LTP,
via potential interactions between the mTOR (mamma-
lian target of rapamycin) and ERK pathways in hippocam-
pal neurons [67]. One of the transcription factors
involved, cAMP-responsive element binding (CREB), has
been identified as critically important for protein synthe-
sis during LTP and long-term memory formation.
The first indications for a role of CREB in synaptic plastic-
ity came from studies with the snail Aplysia, which exhibits
a memory-like behavior for gill withdrawal reflex known
as long-term facilitation (LTF, reviewed in [68]). A couple
of studies demonstrated the requirement and sufficiency
of the CREB pathway for LTF [69-73]. Similar results were
obtained from studies in Drosophila [74,75]. In rodents,
CREB inactivation leads to a decrease in long-term mem-
ory [76-78].
Phosphorylation of Ser133 in CREB was identified as the
key event that must occur in order for CREB to function as
a stimulus-dependent transcriptional activator. After
phosphorylation at Ser133, CREB recruits CREB binding
protein (CBP) to act as a transcriptional coactivator
[79,80]. A number of calcium-dependent signaling path-
ways were shown to result in the nuclear phosphorylation
of CREB at Ser133. Among these are CaMKIV [81-83] and
MAPK/ERKs [57,84-87]. In contrast to CaMKs, ERKs can-Molecular Neurodegeneration 2009, 4:20 http://www.molecularneurodegeneration.com/content/4/1/20
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not directly phosphorylate CREB. Two families of related
kinases were reported to translate the signal from acti-
vated ERKs to CREB. These are the ribosomal S6 kinases
(RSKs) and mitogen- and stress-activated protein kinases
(MSKs) [88,89]. MAPK/ERKs are coupled to CREB activa-
tion by RSK2 [84,90,91]. A role for MSK1 was also
reported in vivo in mice where activation of MAPK, MSK1,
and CREB was found to be absolutely dependent on cal-
cium-stimulated adenylyl cyclase and PKA activities
[92,93]. It appears that CaMKIV- and ERK-induced CREB
stimulation follows different kinetics, with CaMKIV dom-
inating the rapid activation of CREB, whereas MAPK/ERKs
being slower, suggesting that ERKs are required for the
maintenance of CREB phosphorylation and activation
[94,95]. In addition, CREB activation through MAPK/
ERKs seems to be connected to PKA and PKC signaling.
Activation of both PKA and PKC targets ERKs and thereby
phosphorylates CREB. This PKA- and PKC-dependent
phosphorylation of CREB is significantly inhibited by
MEK inhibition indicating that MAPK/ERKs are mediators
of both signals [57].
Thus, calcium is critically involved in synaptic activity and
memory formation by regulating specific signal transduc-
tion pathways that implicate key protein effectors, such as
CaMKs, MAPK/ERKs, and CREB (Figure 1). Properly con-
trolled homeostasis of this calcium signaling not only
supports normal brain physiology but also maintains nor-
mal neuronal integrity and long-term cell survival.
Calcium homeostasis perturbations in 
neurodegenerative diseases
Perturbations in calcium homeostasis were observed in
several neurodegenerative disorders including Alzhe-
imer's disease (AD) [96-100], Parkinson's disease (PD)
[101-103], Huntington's disease (HD) [104-107], and
amyotrophic lateral sclerosis (ALS) [108-111] (see Table
1). Calcium homeostasis disruption implicates several
mechanisms, such as alterations of calcium buffering
capacities, deregulation of calcium channel activities, or
excitotoxicity. Rare examples support a direct causative
role of calcium homeostasis deregulation in neurodegen-
eration. However, compelling evidence supported by an
increasing number of publications on this topic, high-
lights the importance of calcium deregulation in the neu-
rodegenerative process [98,112]. We will focus in this
section on how calcium homeostasis is affected in neuro-
degenerative disorders by taking non exhaustive examples
in AD, PD, HD, and ALS (Figure 2).
Weakening of cell calcium buffering capacity
Different populations of neurons are selectively affected
in different neurodegenerative diseases. The selective vul-
nerability of some neuronal populations can be explained
in part by the decreased expression of some calcium buff-
ering proteins including calbindin-D28K, calmodulin,
and parvalbumin. Calbindin-D28K and parvalbumin are
absent in motoneuron populations lost early in ALS (e.g.
cortical and spinal motoneurons, lower cranial nerve
motoneurons), while motoneurons rarely affected or
damaged late during the disease express markedly higher
levels of these calcium-buffering proteins [110]. The
importance of calcium buffering protein levels for calcium
homeostasis in ALS was confirmed in vivo in parvalbumin
transgenic mice interbred with mutant copper/zinc super-
oxide dismutase SOD1 (mSOD1) transgenic mice, an ani-
mal model for familial ALS. These mice present a
significant reduction in motoneuron loss, had a delayed
disease onset, and a prolonged survival when compared
with mSOD1 transgenic mice [113]. Interestingly, a dra-
matic reduction in calbindin-D28K mRNA and protein
levels has been described in the substantia nigra, hippoc-
ampus, and nucleus raphe dorsalis in brains of patients
with PD [114]. Furthermore, an overall decrease in the
levels of calbindin-D28K and calmodulin has been found
in the temporal, parietal, and frontal cortex of brains of
AD patients [115,116]. In brains of HD patients, a loss of
neurons containing calbindin-D28K has also been
observed [117]. These findings indicate that the decline in
the calcium buffering capacity in brain areas known to be
particularly affected in each of these diseases may contrib-
ute to the neurodegenerative process.
Increased vulnerability to excitotoxicity
Glutamate is the most abundant excitatory neurotrans-
mitter of the mammalian nervous system. At the neuronal
membrane, glutamate binds to ionotropic and metabo-
tropic receptors. Ionotropic receptors include NMDA, kai-
nate, and AMPA receptors. Activation of the ionotropic
receptors leads to channel opening at the plasma mem-
brane and permeability to calcium. Functional AMPARs
are homo- and hetero-oligomeric assemblies composed
of various combinations of 4 possible subunits. The cal-
cium permeability of AMPARs differs markedly according
to whether the GluR2 subunit is present or not in the pro-
tein complex: The presence of GluR2 interfering with the
channel permeability to calcium. In contrast with iono-
tropic receptors, metabotropic receptors are not ion chan-
nels but are also regulators of calcium homeostasis by
mobilizing calcium from internal stores via GTP binding
protein-dependent mechanisms.
Excessive activation of glutamate receptors can result in
neuronal dysfunction and cell death, a process called exci-
totoxicity [118]. Uncontrolled activation of ionotropic
receptors leads to an excessive influx of calcium through
the plasma membrane, which along with impairments of
synaptic activation and neuronal plasticity, activate a
number of calcium-dependent enzymes involved in the
catabolism of proteins, phospholipids, and nucleic acids,Molecular Neurodegeneration 2009, 4:20 http://www.molecularneurodegeneration.com/content/4/1/20
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as well as in the synthesis of nitric oxide (NO). These alter-
ations can potentially lead to cell death through different
pathways, such as membrane break-down, cytoskeletal
alterations, and NO-derived free radical production.
Increased activation of glutamate receptors has been
described in AD, PD, ALS, and HD.
In the case of ALS, in vitro and in vivo findings suggest that
motoneurons are more vulnerable to AMPAR-mediated
excitotoxicity than are other neuronal subclasses [119].
This vulnerability in part reflects the absence of detectable
GluR2 subunit in spinal motoneurons implicating that
they express calcium-permeable AMPARs [120,121]. Exci-
totoxicity appears to be also involved in familial cases of
ALS where mutations in the SOD1 gene are found.
Motoneurons from the SOD1 mutant mice exhibit greatly
increased vulnerability to glutamate toxicity by AMPARs,
which are associated with sustained elevations of intracel-
lular calcium levels, enhanced oxyradical production, and
mitochondrial dysfunction [122].
Many lines of evidence support a role of excessive activa-
tion of glutamate receptors by excitatory amino acids in
the pathogenesis of HD. Neurons expressing high levels of
NMDAR are lost early in the striatum in HD individuals,
and injection of NMDAR agonists into the striatum of
rodents or non-human primates recapitulates the pattern
of neuronal damage observed in HD [106]. Interestingly,
Sun and colleagues showed that polyQ expansions (exp) in
huntingtin (Htt) may promote glutamate-mediated exci-
totoxicity. Normal Htt inhibits channel receptor activity
by binding to NMDA and kainate receptors via post syn-
aptic density 95 (PSD-95). The binding of PSD-95 to
NMDA or kainate receptors causes the clustering of the
receptors at the postsynaptic membrane to regulate
NMDA-dependent LTP and LTD. Httexp  was found to
interfere with the ability of Htt to interact with PSD-95,
causing sensitization of NMDAR and thus promoting neu-
ronal apoptosis induced by glutamate [123].
PD is characterized by a loss of dopamine-containing neu-
rons in the substantia nigra pars compacta. During nigros-
triatal dopaminergic depletion, the glutamatergic
projections (from subthalamic nucleus to the basal gan-
glia output nuclei) become overactive [124]. Several stud-
ies have shown that a pharmacological inhibition of
glutamatergic neurotransmission can ameliorate motor
abnormalities in experimental models of PD [125-128].
Alterations of NMDAR functions in PD include impair-
ments in binding of several NMDAR ligands, including L-
glutamate or the NMDAR interacting antagonists CPP and
MK-801 [102]. Other impairments of NMDAR function in
PD include alterations in NMDAR subunits gene expres-
sion, protein abundance, and phosphorylation [102].
Excitotoxicity also appears to play an important role in the
pathogenesis of AD. The AD brain is characterized by the
presence of lesions, including senile plaques that are
mainly formed by aggregated amyloid-β (Aβ) peptides
[97,129]. Aβ seems to be able to increase the vulnerability
of neurons to excitotoxicity mediated by NMDAR
[96,130]. Aβ oligomers have been found to cause an
increase in NMDAR activity, which might require direct
association between Aβ oligomers and the NR1 subunit of
NMDAR [131]. There is also evidence that glutamate or
other endogenous glutamate receptor agonists are
increased in AD. Furthermore, NMDAR subunits NR1,
NR2A, and NR2B protein levels and phosphorylation are
selectively reduced in AD and these abnormalities corre-
late with the cognitive impairments [132]. Finally, it is
important to note that memantine, a low- to moderate-
affinity NMDAR antagonist, is approved for the treatment
of moderate to severe AD. Clinical trials have shown that
memantine treatment leads to functional improvement in
AD patients [133].
Deregulation of calcium channels
The deregulation of calcium channels other than gluta-
mate receptors is also described in some neurodegenera-
tive diseases. Studies have demonstrated that
autoimmunity may be involved in ALS pathogenesis
[134]. Delbono and colleagues have shown that most
Calcium homeostasis deregulations in neurodegenerative dis- eases Figure 2
Calcium homeostasis deregulations in neurodegen-
erative diseases. AD, PD, HD, and ALS affect cytosolic cal-
cium levels by deregulating different homeostatic control 
mechanisms. NMDAR or AMPAR activities, calcium buffering 
proteins, and mitochondrial functions were found to be 
deregulated in the 4 neurodegenerative conditions. α-Synu-
clein and Aβ peptides, the building blocks of Lewy bodies in 
PD and of senile plaques in AD, respectively, can form cal-
cium-permeable ion channels at the plasma membrane. 
Abnormal ER calcium efflux by a mechanism of oversensitiza-
tion of InsP3R (in HD and FAD) and RyR (in FAD), or of 
inactivation of the ER pump SERCA (in FAD), was also 
observed.
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patients with sporadic ALS possess immunoglobulins
(IgGs) directed against VGCCs and that the titers of these
antibodies correlate with disease progression rates
[135,136]. Interestingly, ALS IgGs passively transferred
into mice selectively increased intracellular calcium and
produced similar ultrastructural changes in motoneurons
than those observed in ALS [137,138]. These results sup-
port the idea that calcium is central in the selective vulner-
ability of motoneurons in ALS. It is important to note,
however, that the notion of autoimmunity in ALS remains
controversial [139,140].
Tang and collaborators have demonstrated that Httexp can
facilitate InsP3R activity. The authors showed that there
are functional interactions at the molecular and cellular
levels between Htt and InsP3R. The expended version of
Htt binds to InsP3R much stronger than the wild type Htt.
This biochemical association is correlated with increased
sensitivity of InsP3R to InsP3 in single channel recordings
of isolated receptors exposed to Httexp and in measure-
ments of calcium transients in medium spiny neurons
transfected with Httexp. The authors have suggested that
Htt directly interacts with the InsP3R1 cytosolic carboxy-
terminal tail and that binding to this limited region of
InsP3R1 is highly dependent on the presence of polyQ
expansions within Htt [141].
Alterations in calcium homeostasis in some neurodegen-
erative diseases could also be the consequence of muta-
tions in ion channels. Our group has recently identified
and characterized a new calcium channel involved in AD
pathogenesis [142]. We have showed that a polymor-
phism in the gene coding for CALHM1 leads to a decrease
in the activity of the channel and is genetically associated
with the risk of developing late-onset AD in large Euro-
pean populations (see section "CALHM1: A novel regulator
of calcium homeostasis and AD pathogenesis"). In ALS
patients, a genome-wide association study identified the
inositol 1,4,5-triphosphate receptor 2 gene (ITPR2) as a
candidate susceptibility gene [143,144]. ITPR2 is a main
regulator of intracellular calcium concentrations. It is also
important to mention that spinocerebellar ataxia type 6
(SCA6) is a neurodegenerative disorder caused by CAG
repeat expansions within the P/Q type calcium channel
CaV2.1 gene and is characterized by predominant degen-
eration of cerebellar Purkinje cells [145-148].
Disruption of mitochondrial calcium homeostasis
Mitochondria are important calcium regulators. Indeed,
mitochondria can take up calcium by an energy-depend-
ent process through the uniporter and thus reduce
cytosolic calcium concentrations. Mitochondria can also
release their calcium content through a Na+/Ca2+
exchanger and the mitochondrial permeability transition
(MPT) pore upon appropriate stimulation. Various fac-
tors, including high mitochondrial calcium levels and
mitochondrial depolarization, trigger MPT pore opening.
Prolonged opening of this pore has been associated with
Table 1: General description of the neurodegenerative diseases discussed in this article
Disease Clinical 
manifestations
Neuronal populations 
affected
Protein aggregates Genetic factors References
Alzheimer's 
disease (AD)
Memory loss and 
behavioral abnormalities.
Loss of neurons and 
synapses in the cerebral 
cortex and certain 
subcortical regions.
Amyloid plaques and 
neurofibrillary tangles.
APP, PS1, PS2, 
APOE4, 
CALHM1...
[96-100]
Parkinson's 
disease (PD)
Resting tremor, postural 
instability, gait 
disturbance, 
bradykinesia, and rigidity.
Dopaminergic neurons of 
the substantia nigra pars 
compacta (SNpc).
Aggregated protein deposits 
named Lewy bodies (LB) 
composed of α-synuclein.
Parkin, DJ-1, 
PINK1, LRRK2
[101-103]
Huntington's 
disease (HD)
Chorea, psychiatric 
disturbances, and 
cognitive impairments.
Loss of medium spiny 
neurons (MSN). The area 
affected are mainly the 
striatum (caudate nucleus, 
putamen, and globus 
pallidus), and also the 
frontal and temporal 
cortex.
Accumulation and aggregation of 
mutant Huntingtin (containing 36 
or more polyglutamine (polyQ) 
expansions in the N-terminal of 
Huntingtin).
Htt [104-107]
Amyotrophic 
lateral sclerosis 
(ALS)
Muscle weakness, 
muscular atrophy, 
spasticity, and eventually 
paralysis.
Motoneurons of the spinal 
cord, cortex and brain 
stem.
Intraneuronal aggregates 
including Bunina bodies, 
ubiquitinated inclusions, 
neurofilament-rich "hyaline 
conglomerate inclusions".
SOD1 [108-111]
PINK1, PTEN-induced putative kinase 1; LRRK2, leucine-rich repeat kinase 2; SOD1, Cu/Zn-superoxide dismutase 1.Molecular Neurodegeneration 2009, 4:20 http://www.molecularneurodegeneration.com/content/4/1/20
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the release of apoptotic factors and cell death. Malfunc-
tions of mitochondria have been associated with various
neurodegenerative diseases. Excitotoxity is one mecha-
nism that eventually leads to mitochondrial dysfunction
and cell death. Other mitochondrial defects independent
of excitotoxicity have also been found [149].
A clear connection has been established between mito-
chondria, calcium, and neurodegeneration in HD. Panov
and colleagues have found that lymphoblast mitochon-
dria from patients with HD have a lower membrane
potential and depolarize at lower calcium loads than
mitochondria from controls do. A similar defect in brain
mitochondria from transgenic mice expressing mutant
Htt has been described [150,151]. The authors suggest
that mitochondrial abnormalities may be due to a direct
binding of mutant Htt on the organelle in neurons [150].
Mutant Htt interaction with mitochondria has later been
confirmed and a recombinant truncated mutant Htt pro-
tein was found to directly induce MPT pore opening in
isolated mouse liver mitochondria. Importantly, the
mutant Htt protein significantly decreased the calcium
threshold necessary to trigger MPT pore opening [152]. A
marked decrease in mitochondrial complex II activity
(succinate dehydrogenase, SD) has been found in the
brains of HD patients. This inhibition of mitochondrial
complex II induces a long-term potentiation of NMDA-
mediated synaptic excitation in the striatum and is
dependent on dopamine [153].
In sporadic ALS, defective electron transport chain func-
tion, perturbed mitochondrial calcium buffering, oxida-
tive stress, and altered mitochondrial ultra-structure have
been observed [154]. Mitochondrial abnormalities have
also been found in patients with ALS and in transgenic
mice with mutant SOD1 [155,156]. In G93A SOD1
mutant transgenic mice, a significant decrease in mito-
chondrial calcium loading capacity in brain and spinal
cord was found [157]. Mutant SOD1 may also affect intra-
cellular calcium levels through a direct toxic effect on
mitochondria [158,159].
Defects in mitochondria have also been observed in AD.
Mitochondria from AD patient fibroblasts take up less cal-
cium compared to normal controls and they sequester
more calcium following oxidative stress [160]. Pyramidal
hippocampal neurons show increased levels of mitochon-
drial DNA and proteins in the cytoplasm and lysosomes
[161]. Besides, the Aβ peptide was found in mitochondria
from brains of transgenic mice and AD patients and is
associated with diminished enzyme activity of the respira-
tory chain complexes III and IV, and with a reduction in
the rate of oxygen consumption [162]. Recent evidence
also indicates that Aβ can be transported into mitochon-
dria via the translocase of the outer membrane TOM
[163]. Furthermore, Aβ oligomers were proposed to
induce a mitochondrial calcium overload resulting in a
massive calcium influx and toxicity in neurons [164].
Mitochondrial Aβ accumulation in AD neurons may thus
potentiate calcium-induced opening of the MPT pore and
mitochondrial swelling [165,166].
Strong evidence also implicates mitochondria impair-
ments in PD pathogenesis. Dysfunctional mitochondria
with reduced activities of complex I and of NADH cyto-
chrome c reductase in neurons from the substantia nigra
have been observed in PD [167]. Evidence that mitochon-
dria defects are involved in PD also comes from toxic sub-
stances known to induce Parkinson-like symptoms, such
as MPTP and rotenone [168-170]. The active metabolite
of MPTP, the 1-methyl-4-phenylpyridinium ion (MPP+),
is an inhibitor of the mitochondrial electron transport
chain complex I and a substrate of the dopamine trans-
porter. Thus, MPP+ can accumulate in dopaminergic neu-
rons, where it confers toxicity and leads to neuronal death
through complex I inhibition. This has many deleterious
consequences, including increased free radical produc-
tion, oxidative stress, and decrease ATP production, caus-
ing increased intracellular calcium concentrations,
excitotoxicity, and NO-related cellular damage. Likewise,
rats administered with the highly selective complex I
inhibitor rotenone developed a PD-like syndrome charac-
terized by neuronal degeneration and formation of α-
synuclein rich inclusion bodies [171].
Calcium homeostasis deregulations in AD
A large body of literature supports the notion that a
deranged intracellular calcium signaling occurs in AD and
may be involved in both APP processing deregulation and
neurodegeneration [7,99,172]. Several in vitro and in vivo
studies have identified calcium signaling pathways rele-
vant to AD pathogenesis.
Recently, two studies have addressed the important ques-
tion of neuronal calcium dynamics in vivo in the brain of
APP-expressing mouse models. Using brain injections of
calcium indicator dyes, the authors observed a calcium
overload in dendritic spines [173] and an increase in the
frequency of spontaneous calcium transients [174] in
neurons adjacent to cortical amyloid plaques. Kuchib-
hotla and colleagues showed that senile plaques impaired
neuritic calcium homeostasis in vivo and result in a struc-
tural and functional disruption of neuronal networks
[173]. Busche and colleagues used double transgenic
APP23xPS45 mice to visualize in vivo amyloid plaques
and cortical neurons. They sequentially injected the cal-
cium indicator dye Oregon Green 488 BAPTA-1 AM in
order to monitor calcium transient and firing of action
potentials in neurons and thioflavin S to label fibrillar
amyloid deposits. In the transgenic mice, they found thatMolecular Neurodegeneration 2009, 4:20 http://www.molecularneurodegeneration.com/content/4/1/20
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only half of the neurons were active in the normal fre-
quency range, whereas the remaining neurons were either
silent or hyperactive. They further demonstrated that
these hyperactive neurons were found in close proximity
to the plaque borders, whereas the proportion of silent
cells gradually increases at greater distances from the
plaques. They observed a strict correlation between the
formation of amyloid plaques, the appearance of hyperac-
tive neurons, and the impairment of the animal's learning
capability [174]. These data are important because they
provide in vivo evidence for a calcium-dependent mecha-
nism of disturbed neuronal and synaptic function in AD.
They also represent an intriguing observation because cal-
cium homeostasis in neurons and in dendritic spines sup-
ports neural networks directly relevant to learning and
memory.
Specific soluble oligomeric species of Aβ were found to be
synaptotoxic by affecting LTP and memory in rodents
[175-179]. Several studies demonstrated that Aβ-induced
synaptic dysfunction is linked to altered calcium signal-
ing. Exposure of cortical neurons to Aβ peptides destabi-
lized calcium homeostasis and rendered neurons more
vulnerable to excitoxicity [130,180]. Application of Aβ40
to cortical synaptosomes and cultured neurons was also
found to increase calcium influx via activation of VGCCs
[181]. CaMKII autophosphorylation and subsequent
phosphorylation of the AMPAR GluR1 subunit was
strongly inhibited by application of Aβ42 peptides during
hippocampal LTP [182]. Furthermore, soluble oligomeric
Aβ isolated from AD patient brains was proposed to be
toxic by affecting mGluRs and NMDARs [183]. Similar to
α-synuclein, Aβ adopts a β-sheet structure and was also
proposed to act by forming calcium pores [100,184-187].
Together, these studies support the notion that defects in
calcium-dependent synaptic activity are likely to be
responsible for the neurotoxic effect of Aβ. Although prox-
imity to senile plaques, which mostly contain deposited
Aβ, seems to affect calcium-dependent synaptic functions
in vivo, it is conceivable to believe that plaques might con-
stitute a reservoir for soluble Aβ species, including oligo-
meric neurotoxic species. The "calcium poisoning" effect
observed  in vivo in neurons surrounding the amyloid
deposits might therefore be due to released soluble neuro-
toxic oligomeric Aβ species.
APP, tau, and calcium homeostasis
A sustained increase in intracellular calcium can, per se,
lead to neurodegeneration and cell death. However, cal-
cium homeostasis deregulation can also affect the fate of
proteins involved in the pathogenesis of the disease, as it
is the case for tau and Aβ in AD. In addition to the Aβ
plaques, histopathological studies of the AD brain have
revealed the presence of dramatic ultrastructural changes
triggered by other lesions, the neurofibrillary tangles,
which consist of aggregated hyperphosphorylated tau pro-
teins [97,129,188]. The state of tau phosphorylation and
proteolysis can be regulated by calcium-dependent mech-
anisms. CaMKII can phosphorylate tau [189]. Cyclin-
dependent kinase 5 (cdk5), another kinase involved in tau
phosphorylation [190], is indirectly activated by the cal-
cium-activated protease calpain. Indeed, cdk5 has to be
associated with its regulatory subunit, p35 to be activated.
Conversion of p35 to p25 deregulates cdk5 activity, result-
ing in an increased cdk5 kinase activity [191]. Calpain
cleaves p35 into p25, and thus controls cdk5 activation
[192]. Furthermore, tau is dephosphorylated by the cal-
cium/calmodulin-dependent phosphatase, calcineurin
[193]. Calpain was also proposed to directly participate in
tau proteolysis and degradation [194]. Interestingly, inhi-
bition of calpains was recently found to improve memory
and synaptic transmission in a mouse model of AD [195].
Pharmacological inhibition of calpains restored normal
synaptic function in both hippocampal cell cultures and
hippocampal slices from APP/PS1 mice. Calpain inhibi-
tion also improved spatial working memory and associa-
tive fear memory in these mice. These beneficial effects of
calpain inhibition were associated with restoration of nor-
mal phosphorylation levels of CREB [195]. Interestingly,
overexpression of tau-tubulin kinase-1 (TTBK1), a kinase
phosphorylating tau and activating calpain I and cdk5, led
to the formation of neurofilament aggregates and age-
dependent memory impairments in a transgenic animal
model [196]. The authors also determined that TTBK1
expression resulted in a downregulation of hippocampal
NMDAR NR2B subunits, suggesting a potential cross-talk
between tau phosphorylation, calcium homeostasis
deregulations, and memory deterioration.
Sequential endoproteolysis of APP (amyloid-β precursor
protein) by the aspartyl protease β-secretase/BACE1 and
by the presenilin/γ-secretase complex leads to the produc-
tion of Aβ [197,198]. In an alternative non-amyloidog-
enic pathway, APP is endoproteolyzed within the Aβ
region by α-secretase to generate the soluble N-terminal
fragment sAPPα, a protein that might possess some neu-
roprotective properties [198]. APP processing can be regu-
lated by calcium signaling and inversely, APP metabolism
can influence calcium signaling. It was shown that cal-
cium influx mediated by calcium ionophores or by mem-
brane depolarization and channel opening, leads to
increased production of Aβ [199,200]. Conversly, inhibi-
tion of SERCA pumps with thapsigargin and increased
cytosolic calcium levels from ER calcium depletion,
diminished Aβ generation [201]. It seems that the effect of
calcium on APP processing might depend on the source of
the ions and on the mechanism involved. Calcium has
also been involved in the stimulation of sAPP release
[142,201,202]. Moreover, sAPPα can cause a rapid and
prolonged reduction in intracellular calcium concentra-
tions and can protect neurons against glutamate neuro-
toxicity by raising the excitotoxic threshold [180,203]. InMolecular Neurodegeneration 2009, 4:20 http://www.molecularneurodegeneration.com/content/4/1/20
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addition, carboxy-terminal fragments (CTs) of APP can
disrupt calcium homeostasis and render neuronal cells
vulnerable to excitotoxicity. It was found that a recom-
binant CT105 of APP could inhibit Na+/Ca2+ exchanger
activity in SK-N-SH cells [204] and rendered SK-N-SH
cells and rat primary cortical neurons more vulnerable to
glutamate-induced excitotoxicity [205]. Importantly, both
Aβ and CT105 have been shown to shorten the duration
of high frequency stimulation-induced LTP in rat hippoc-
ampus  in vivo [206]. Moreover, adult transgenic mice
expressing the CT104 of APP demonstrated spatial learn-
ing deficits and defects in the maintenance of LTP [207].
Calcium signaling alterations are also observed in preseni-
lin-1-/- and APP-/- cells and can be reversed by reintroduc-
tion of AICD, the C-terminal domain of APP produced by
γ-secretase. This suggests that AICD could also be involved
in the regulation of calcium signaling [208].
Presenilins in calcium homeostasis
Presenilins (PSs) are multipass transmembrane proteins
involved in many cases of early-onset familial AD (FAD)
and represent the catalytic core of the γ-secretase activity
[197]. In 2006, it has been proposed that PS holoproteins
have calcium leak properties at the ER membrane. The
authors showed that PSs could form low-conductance
divalent-cation-permeable ion channels in planar lipid
bilayers, a property significantly reduced by several FAD-
linked PS mutations [209,210]. Furthermore, it has been
shown that PSs can physically interact with the InsP3
[211] and ryanodine [212] receptors and facilitate their
calcium gating activity at the ER membrane. Overexpres-
sion of several FAD PS mutants consistently generated a
robust increase in the gating of InsP3R, as compared to
wild type PSs [211], suggesting that the pathogenic muta-
tions exaggerate cellular calcium signaling in response to
ligand activation. The ER calcium pump SERCA was also
found to form a protein complex with endogenous PSs, an
interaction that influences SERCA function by controlling
ER calcium sequestration and InsP3-mediated calcium
liberation [213]. Several of these studies have also pro-
posed that increased ER calcium release via InsP3Rs or
RyRs or via modulation of SERCA may modulate APP
processing and facilitate Aβ accumulation. Together these
studies indicate that disease-linked PS mutations could
impact APP metabolism by affecting ER calcium dynamics
at multiple levels (Figure 2). Nevertheless, APP metabo-
lism involves a complex series of events and the direct
influence of calcium signaling on this process remains to
be clearly addressed [7].
CALHM1: A novel regulator of calcium homeostasis and 
AD pathogenesis
A number of neurodegenerative disorders are caused by
mutations in genes expressed principally in the central
nervous system. This is the case for the brain proteins tau
and  α-synuclein, which are genetically linked to auto-
somal dominant forms of frontotemporal dementia [214]
and PD [215], respectively. Recently, we postulated that
susceptibility to AD could come from genes predomi-
nantly expressed in affected brain regions, such as the hip-
pocampus. By using a tissue-expression profiling method
to screen for genes predominantly expressed in the hip-
pocampus and located in linkage regions for AD, our
group identified the CALHM1 gene, located on chromo-
some 10. CALHM1 codes for a protein of neuronal origin
that shares sequence similarities with NMDAR and that
controls both cytosolic calcium concentrations [142] and
ERK1/2 activation [216]. Voltage-clamp analyses further
revealed that CALHM1 generates a calcium-selective cat-
ion current at the plasma membrane [142]. Importantly,
we also determined that the frequency of the rare allele of
the rs2986017 SNP (single nucleotide polymorphism) in
CALHM1, which results in the P86L substitution, is signif-
icantly increased in AD cases in five independent cohorts.
Further investigation demonstrated the functional signifi-
cance of the rs2986017 SNP by showing that the P86L
polymorphism promotes Aβ accumulation via a loss of
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The role of CALHM1 in calcium signaling: Relevance 
for APP metabolism and AD pathogenesis. CALHM1 
is a cell surface protein of neuronal origin that shares 
sequence similarities with NMDAR. CALHM1 expression 
generates a calcium-selective cation current at the plasma 
membrane and controls cytosolic calcium concentrations, a 
mechanism that may lead to ERK1/2 activation (left panel). 
Importantly, the P86L mutation in CALHM1, which we found 
associated with an increased risk for AD in European popula-
tions, leads to an inhibition of the control of APP processing 
by CALHM1 (right panel). Consequently, the P86L mutation 
leads to a derepression of the effect of CALHM1 on Aβ 
accumulation and thus to an increase of Aβ levels. P86L-
CALHM1 promotes Aβ accumulation via a loss of CALHM1 
control on calcium permeability and cytosolic calcium levels 
[142]. Therefore, CALHM1 is a component of a novel cere-
bral calcium channel family involved in calcium signaling and 
Aβ metabolism, and thus may represent an important player 
in the calcium homeostasis deregulations observed in AD 
pathogenesis.
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CALHM1 control on calcium permeability and cytosolic
calcium levels [142]. Together, this work provides strong
evidence that CALHM1 is a component of a novel cerebral
calcium channel family involved in Aβ metabolism and
that CALHM1 polymorphisms may influence AD risk. The
identification of CALHM1 as a key modulator of calcium
homeostasis and Aβ levels provides strong support for the
calcium hypothesis of AD. This work is also an important
step towards understanding the potential pathological
cross talk between calcium signaling disturbances, path-
ways of Aβ accumulation, and neurodegeneration (Figure
3).
Conclusion
The central role of calcium signaling in brain functions
underlines its potential relevance for neurodegeneration.
This notion is now supported by overwhelming evidence
in several neurodegenerative disorders of the CNS, such as
AD, PD, or HD, and in the motoneuron disorder ALS. The
apparent complexity of the different calcium-dependent
mechanisms involved in neuronal death in these diseases,
reflects the sophistication of the pathways available to
control normal calcium homeostasis. This complexity
makes the identification of precise and common neuro-
toxic molecular events between these disorders challeng-
ing. Nevertheless, it is likely that a precise definition of the
calcium signaling failure in neurodegeneration will one
day emerge and facilitate the identification of novel ther-
apeutic targets.
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